High-Intensity Interval Exercise in Bronchiectasis Patients
3. september 2026 oppdatert av: Saglik Bilimleri Universitesi
Investigation of the Effectiveness of High-Intensity Interval Exercise in Bronchiectasis Patients
The aim of our study is to investigate the effect of high-intensity interval exercise (HIIE) on the symptoms of bronchiectasis in patients with the disease. The main questions it aims to answer are:
- Does HIIE improve respiratory function in patients with bronchiectasis?
- Does HIIE increase functional capacity, peripheral muscle strength, and quality of life in patients with bronchiectasis?
- Does HIIE reduce the severity of dyspnea, cough symptoms, and fatigue in patients with bronchiectasis?
The study was designed as a randomized controlled trial. Participants were divided into two groups: intervention and control.
Participants will:
The intervention group will receive HIIE training three days a week along with airway clearance techniques.
The control group would receive only airway clearance techniques. Airway clearance techniques will be provided clinically (three days a week) and at home, according to the needs of the individuals each day of the week.
Studieoversikt
Status
Rekruttering
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Antatt)
42
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Mustafa Ertuğrul YAŞA, Associate Professor
- Telefonnummer: 0312 304 61 97
- E-post: mustafaertugrul.yasa@sbu.edu.tr
Studiesteder
-
-
Keçiören
-
Ankara, Keçiören, Tyrkia (Türkiye), 06018
- Rekruttering
- Gulhane Faculty of Physiotherapy and Rehabilitation
-
Ta kontakt med:
- Telefonnummer: 0 312 567 15 00
- E-post: bilgiedinme@sbu.edu.tr
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Ja
Beskrivelse
Inclusion Criteria:
- Being over 18 years of age
- Having a clinical and radiological diagnosis of non-cystic fibrosis bronchiectasis
- Absence of cognitive impairment (MMT>24)
- Being clinically stable (not having experienced any exacerbation in the last 4 weeks)
Exclusion Criteria:
- Presence of any disease that may affect compliance with exercise (Unstable angina (within the last month), recent myocardial infarction (heart attack), uncontrolled arrhythmias, severe aortic stenosis, decompensated heart failure, severe pulmonary hypertension, acute respiratory tract infection, severe hypoxemia at rest (<85%), orthopedic or neurological problems that impede walking, severe anemia, acute infections, very high resting blood pressure (systolic >180-200 mmHg, diastolic >100-110 mmHg), psychological issues, etc.)
- Smoking
- Chronic alcoholism that may affect exercise safety (More than 1 drink per day on average for women, more than 2 drinks per day on average for men (1 standard drink ≈ 10-14 g of alcohol)
- Presence of any respiratory tract disease other than bronchiectasis
- After incremental shuttle walk test arterial oxygen saturation <80%
- Participation in a structured exercise program within the last 6 months
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Intervention
Patients in this group will perform airway clearance techniques along with high-intensity interval exercise.
|
The high-intensity interval exercise (HIIE) protocol (4×4 model: 4 minutes at 85-95% maximum heart rate, with 3 minutes of active recovery at 60-70% in between), will be applied 3 days a week for 8 weeks using a treadmill or cycle ergometer, taking into account the participants' physical characteristics and safety requirements.
Among the airway clearance techniques, the active cycle of breathing techniques (ACBT) and manual techniques will be applied.
Additionally, the autogenic drainage technique will be taught to patients for them to practice at home.
Airway clearance techniques will be demonstrated to the patients practically and they will be asked to perform them daily (3 days a week in the clinic) as needed.
|
|
Aktiv komparator: Control
Patients in this group will only undergo airway clearance techniques.
|
Among the airway clearance techniques, the active cycle of breathing techniques (ACBT) and manual techniques will be applied.
Additionally, the autogenic drainage technique will be taught to patients for them to practice at home.
Airway clearance techniques will be demonstrated to the patients practically and they will be asked to perform them daily (3 days a week in the clinic) as needed.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Functional Performance
Tidsramme: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study
|
Functional performance will be measured using an incremental shuttle walk test.
|
At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Maximal Inspiratory Pressure (PImax)
Tidsramme: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
|
Inspiratory muscle strength will be assessed by measuring the maximal inspiratory pressure (PImax) using an electronic, portable, intraoral pressure measuring device.
PImax represents the maximum negative pressure generated during a forceful inhalation against an occluded airway.
Results will be reported in centimeters of water (cmH2O), with higher absolute values indicating greater inspiratory muscle strength.
|
At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
|
|
Maximal Expiratory Pressure (PEmax)
Tidsramme: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
|
Expiratory muscle strength will be assessed by measuring the maximal expiratory pressure (PEmax) using an electronic, portable, intraoral pressure measuring device.
PEmax represents the maximum positive pressure generated during a forceful exhalation against an occluded airway.
Results will be reported in centimeters of water (cmH2O), with higher values indicating greater expiratory muscle strength.
|
At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
|
|
Forced Vital Capacity (FVC)
Tidsramme: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
|
Forced Vital Capacity (FVC) is the total volume of air that can be exhaled forcefully and completely after a maximal inspiration.
It is measured using spirometry to assess overall lung volume and capacity.
The results will be reported as an absolute volume in Liters (L).
|
At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
|
|
FEV1 (Forced Expiratory Volume in 1 Second)
Tidsramme: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
|
Forced Expiratory Volume in 1 second (FEV1) is the volume of air forcefully exhaled during the first second after a maximal inspiration, measured using spirometry.
Outcomes are reported in absolute volume (Liters) and % to evaluate airway obstruction and overall pulmonary function.
|
At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
|
|
FEV1/FVC
Tidsramme: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study
|
FEV1/FVC(%) will be calculated using the FEV1 and FVC values obtained from the pulmonary function test.
|
At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study
|
|
Fatigue
Tidsramme: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study
|
To assess the severity of fatigue and its impact on daily life, the Fatigue Severity Scale (FSS), a self-report scale, will be used.
The scale consists of 9 items, each scored between 1 (strongly disagree) and 7 (strongly agree).
The average score is calculated by dividing the total score by the number of items, with higher scores indicating more severe fatigue.
A score of 4 or higher generally indicates severe fatigue.
|
At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study
|
|
Dyspnea Severity
Tidsramme: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
|
Dyspnea severity will be assessed using the Modified Medical Research Council dyspnea scale.
The scale classifies dyspnea on a five-point scale from 0 to 4; a score of 0 indicates dyspnea occurring only during strenuous exercise, while a score of 4 describes significant shortness of breath even during the mildest daily activities.
|
At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
|
|
The Bronchiectasis Health Questionnaire
Tidsramme: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study
|
The Bronchiectasis Health Questionnaire (BHQ) will be used to assess disease-specific quality of life.
The BHQ is a patient-completed scale consisting of 10 items that evaluates symptom burden, physical function, and the impact of the disease on daily life.
Each item is scored between 0 and 7, and the total score ranges from 0 to 70; higher scores indicate better health status and quality of life.
|
At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study
|
|
Cough Questionnaire
Tidsramme: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
|
The Leicester Cough Questionnaire (LCQ) is a disease-specific, patient-completed scale developed to assess the impact of cough on quality of life in individuals with chronic cough.
The LLC consists of 19 items and covers three sub-dimensions: physical, psychological, and social.
Each item is scored between 1 and 7, and the average of the sub-dimension scores is calculated and summed to obtain a total score ranging from 3 to 21; higher scores indicate better quality of life and less cough-related impact.
|
At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
27. mars 2026
Primær fullføring (Antatt)
31. desember 2026
Studiet fullført (Antatt)
29. mai 2027
Datoer for studieregistrering
Først innsendt
21. april 2026
Først innsendt som oppfylte QC-kriteriene
3. september 2026
Først lagt ut (Faktiske)
4. september 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
4. september 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
3. september 2026
Sist bekreftet
1. april 2026
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2026-085
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
IPD-planbeskrivelse
Due to patient confidentiality, data will not be shared.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .